Table 2.

Baseline characteristics of the 160 CTEPH patients treated with PEA, BPA (with or without MT) and with MT alone (riociguat/sildenafil).

Variable	All patients (n = 160)	PEA (n = 31)	BPA (n = 58)	MT (n = 69)	p value
Age, years	63.2 ± 15.4	50.9 ± 14.7	62.9 ± 15.1	68.9 ± 12.7	<0.01
Gender, female	95 (59%)	17 (55%)	33 (57%)	45 (65%)	0.41
History of acute pulmonary embolism	118 (74%)	26 (84%)	43 (74%)	49 (71%)	0.29
Thrombophilia	18 (11%)	8 (26%)	6 (10%)	4 (6%)	0.01
Cancer history	17 (11%)	1 (3%)	6 (10%)	10 (14%)	0.27
Splenectomy	10 (6%)	1 (3%)	6 (10%)	2 (3%)	0.28
NT-proBNP, pg/ml	2639 ± 3926	1894 ± 2475	3005 ± 4650	2666 ± 3772	0.47
6MWT, m	310 ± 128	328 ± 131	342 ± 142	280 ± 354	0.09
WHO functional class I/II/III/IV	0/31(19%) /110(69%) /19(12%)	0/5(16%) /20(65%) /6(19%)	0/11(19%) /39(67%) /8(14%)	0/15(21%) /51(72%) /5(7%)	-

BPA, balloon pulmonary angioplasty; CTEPH, chronic thromboembolic pulmonary hypertension; MT, medical therapy (riociguat/sildenafil) alone; NT-proBNP, N-terminal pro-brain natriuretic peptide; PEA, pulmonary endarterectomy; WHO, World Health Organization; 6MWT, 6-minute walk test.

Data are presented as mean ± SD or count (percentage).